Profiling cell signaling pathway activity
Unravelling the molecular phenotype
Want to know more about OncoSignal?
We will get in touch with you as soon as possible.
QIAGEN and Philips collaborate to develop CDX tests based on OncoSignal technology
Watch the Qiagen webinar (on demand):
Signaling pathway CDx for therapy response prediction
With this webinar, we announce a partnership between QIAGEN and Philips in the development of companion diagnostics based on OncoSignal pathway activity tests for therapy response prediction.
Recent scientific publication
"Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer", published in Cancers.
In this study, we investigated heterogeneity, using novel assays to measure activity of tumor-driving signal transduction pathways, e.g., estrogen receptor and PI3K pathways, in multiple samples distributed across the tumor and in metastases.
Collaboration with Erasmus MC Cancer Institute to improve the diagnostics of bladder cancer patients
Together with the Erasmus MC Urothelial Cancer Research Group (EUCRG) from the Department of Urology, we have completed a pilot study investigating if OncoSignal is able to predict which high-risk non-muscle-invasive bladder cancer patients treated with BCG have a high risk of developing progressive disease. The promising results have led to a collaboration to perform OncoSignal on a large series of bladder cancer patients.
The aim of this study is to investigate whether OncoSignal could play a supporting role in treatment choice of bladder cancer patients. Since there is currently a global shortage of BCG, alternative treatment strategies for this patient group are essential.
Philips Pathway Activity Profiling OncoSignal
A number of cell signal transduction pathways are known to play a role in the development of cancer. OncoSignal helps to gain insight into the functional activity of these underlying tumor driving signaling pathways. mRNA levels transcribed from direct target genes regulated by the pathway transcription factors are measured and translated into a quantitative pathway activity scores. The activity score of each pathway is reported on a scale from 0 to 100, resulting in a quantitative characterization of the cell molecular phenotype. OncoSignal can support drug development, patient stratification for clinical trials, and cancer research.
For examples on the use of OncoSignal, please request the OncoSignal application note via [email protected]. *For Research Use Only – not for use in diagnostic procedures.
OncoSignal products and services
Test for in-house use
OncoSignal Test
Service testing
OncoSignal Service
Data analysis service
OncoSignal Data Service
NF-КB* pathways
* Under development.
** Please contact us for specific requirements.
OncoSignal is available for Research Use Only – not for use in diagnostic procedures.
Resources
For copies of one of the below mentioned publications and posters, please email us at [email protected].
Scientific publications
Posters
Explore OncoSignal Test for in-house use
Measure the activity of the ER, AR, PI3K and MAPK signaling pathway in your molecular biology laboratory.
This is what your colleagues say about OncoSignal
“Having information regarding signaling pathways that could underlie critical immunologic populations within the tumor microenvironment may be pivotal in understanding how drugs affect the cancer. I am very interested in new technologies that I can use to investigate signaling pathway activity in cancer cells and immune cells for my research in this area”.
Susan F. Slovin, MD, PhD
Professor of Medicine, Weill-Cornell Medical College
Attending Physician in the Genitourinary Oncology Service,
Sidney Kimmel Center for Prostate and Urologic Cancers,
Memorial Sloan-Kettering Cancer Center, New York, USAThis is what your colleagues say about OncoSignal
“High grade serous ovarian carcinoma is still a hard to treat cancer. During the last 20 years we have hardly seen an improvement of survival rates. Recently, we have demonstrated that OncoSignal helps to understand the molecular mechanisms driving high grade serous ovarian cancer in individual patients helping future selection of more effective personalized therapies with targeted drugs. We aim to start a prospective study to further investigate the potential of OncoSignal in patients with ovarian carcinoma”.
Jurgen M. Piek, MD, PhD
Gynaecological Oncologist, Department of Obstetrics and Gynecology,
Catharina Cancer Institute, Catharina Hospital, Eindhoven, The Netherlands
This is what your colleagues say about OncoSignal
"Nowadays, next-generation sequencing by using large panel is commonly recognized as a useful approach to improve cancer patient care. However, estimating the activity of specific pathways rather than single genes aberration may represent a more relevant approach to propose personalised cancer treatments by identifying the main driving mechanisms in each tumour. In this regard, Oncosignal represents a key innovation that can improve dramatically the capacity of molecular tumor board to recommend the right treatment for the right patient".
Prof. Antoine Italiano, MD, PhD
Head Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France
Head Precision Medicine program, Gustave Roussy, Paris, France
This is what your colleagues say about OncoSignal
"OncoSignal Pathway Activity Profiling, a functional assay with a clear read out, has the potential to set a new standard for transforming precision oncology and may provide improved therapy selection options".
Anthony M. Magliocco, MD, PhD
Founder & CEO
Protean BioDiagnostics
Tampa/St. Petersburg, Florida, USA
Clinical Advisory Board
We are pleased to receive guidance and support by international experts:
PACMAN study supported by EIT Health
Functional signaling Pathway ACtivity complementing DNA Mutation ANalysis for precision medicine (PACMAN)
The PACMAN study, in collaboration between Institute Gustave Roussy and Philips, will test how well the OncoSignal solution increases the effectiveness of new, personalized cancer therapy. Significant progress has been made with targeted drugs that block tumor-driving molecular pathways, but it is still difficult to predict how patients will respond. OncoSignal was designed to improve selection of optimal personalized therapy for individual patients and will contribute to disruption of cancer care by moving from treatment based on cancer type to tumor biology. Assessment of the functional molecular phenotype will provide improved therapy response prediction compared to DNA genotyping analysis alone. The project promises to improve clinical outcomes, especially for hard-to-treat cancers, reduce unnecessary side effects from ineffective therapies and save costs due to more effective (personalized) therapies.
First results at ASCO and AACR 2020
For more information, please visit www.eithealth.eu/pacman.
Contact us
Philips Molecular Pathway Diagnostics
High Tech Campus 11 5656 AE Eindhoven The Netherlands Phone: +31 40 2730155 Email: [email protected]
